Compass Therapeutics (CMPX) Assets Average (2018 - 2026)
Compass Therapeutics recorded quarterly Assets Average of $212.4 million in Q1 2026, down 5.79% quarter-over-quarter from $225.4 million in Q4 2025, and up 56.24% year-over-year from $135.9 million in Q1 2025.
Compass Therapeutics' Assets Average history runs 9 years deep, the most recent figure standing at $212.4 million for Q1 2026.
- In Q1 2026, Assets Average rose 56.24% year-over-year to $212.4 million; the TTM figure through Mar 2026 stood at $212.4 million (up 56.24% YoY), while the FY2025 annual figure was $180.0 million, up 21.1% from the prior year.
- Assets Average came in at $212.4 million for Q1 2026 at Compass Therapeutics, down from $225.4 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $225.4 million in Q4 2025 to a low of $124.1 million in Q2 2025.
- A 5-year average of $164.3 million and a median of $159.0 million in 2024 frame the typical range for Assets Average.
- Across the five-year window, Assets Average surged 199.99% in 2022 and declined 21.66% in 2025, its largest moves.
- Compass Therapeutics' Assets Average stood at $163.7 million in 2022, then dropped by 0.17% to $163.5 million in 2023, then slipped by 11.43% to $144.8 million in 2024, then surged by 55.7% to $225.4 million in 2025, then slipped by 5.79% to $212.4 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $212.4 million, $225.4 million, and $174.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 13.04 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 33.42 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.72 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 331.70 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 40.89 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 26.06 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 26.03 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 40.71 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 5.05 Bn |
| 10 | Compass Therapeutics | 418.47 Mn | 223.78 Mn | - | 212.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 212.38 Mn |
| Dec 31, 2025 | 225.42 Mn |
| Sep 30, 2025 | 173.98 Mn |
| Jun 30, 2025 | 124.07 Mn |
| Mar 31, 2025 | 135.93 Mn |
| Dec 31, 2024 | 144.78 Mn |
| Sep 30, 2024 | 152.38 Mn |
| Jun 30, 2024 | 158.38 Mn |
| Mar 31, 2024 | 159.01 Mn |
| Dec 31, 2023 | 163.46 Mn |
| Sep 30, 2023 | 174.61 Mn |
| Jun 30, 2023 | 183.58 Mn |
| Mar 31, 2023 | 193.81 Mn |
| Dec 31, 2022 | 163.74 Mn |
| Sep 30, 2022 | 134.05 Mn |
| Jun 30, 2022 | 143.41 Mn |
| Mar 31, 2022 | 150.16 Mn |
| Dec 31, 2021 | 94.33 Mn |
| Mar 31, 2021 | 50.05 Mn |
| Dec 31, 2020 | 56.30 Mn |
| Sep 30, 2020 | 65.57 Mn |
| Jun 30, 2020 | 35.23 Mn |
| Mar 31, 2020 | 15.19 Mn |
| Dec 31, 2019 | 15.19 Mn |
| Sep 30, 2019 | 2,874.00 |
| Jun 30, 2019 | 4,866.00 |
| Mar 31, 2019 | 4,772.50 |
| Dec 31, 2018 | 3,562.50 |
| Sep 30, 2018 | 4,838.50 |
| Jun 30, 2018 | 3,628.00 |